Mape Pharmascience Llp - Due diligence report

A 360° intelligence report on Mape Pharmascience Llp: trust score, financial health, credit view, compliance, directors, growth and distress…

2016-05-27 Mumbai, Maharashtra Active
Share
View plans
MP Mape Pharmascience Llp
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Mape Pharmascience Llp — 360° Intelligence Report

Generated from MCA filings & public records
87/100
Trust Score
Low Risk

Mape Pharmascience Llp is assessed as Low Risk with a Trust Score of 87/100. Mape Pharmascience Llp is an active limited liability partnership incorporated in 2016, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 03 Jul 2026 from the latest processed filings. Mape Pharmascience Llp snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
87/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • Profitable - internal accruals available.

Charges position: 1 open (40.00 cr) · 4 satisfied (303.50 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Idbi Trusteeship Services Limited2 48.0 cr
Axis Bank Limited1 48.0 cr
Rbl Bank Limited1 48.0 cr
Piramal Trusteeship Services Private Limited1 48.0 cr
Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
DEEPAK MOHAN 01234567 Director 01/04/2018 6 yrs Approved
JACOB MATHEW 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 90
Growth signals & trust indicators
Profit expanded 38% year-on-year.
Operating for 10+ years.
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence90/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment67/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 40.00 cr already registered.
  • Compliance record supports lending.
Investor view66/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
31 Mar 2025
Last AGM held
Annual general meeting
Latest balance sheet
Filed with ROC
22 Jul 2024
Director appointed
DEEPAK MOHAN (Designated Partner)
27 May 2024
Charge created
Piramal Trusteeship Services Private Limited - 40.00 cr
07 May 2024
Charge satisfied
Rbl Bank Limited
28 Mar 2024
Charge satisfied
Axis Bank Limited
14 Oct 2021
Charge satisfied
Idbi Trusteeship Services Limited
10 Apr 2021
Director ceased
VISHWANATH KANTHAPPA POOJARI
23 Feb 2020
Director ceased
RAMPRASAD MATHRUBUTHAM
22 Feb 2018
Charge created
Rbl Bank Limited - 51.00 cr
09 Feb 2018
Charge created
Axis Bank Limited - 82.50 cr
31 Jan 2018
Charge satisfied
Idbi Trusteeship Services Limited
22 Nov 2017
Charge created
Idbi Trusteeship Services Limited - 30.00 cr
23 Aug 2016
Charge created
Idbi Trusteeship Services Limited - 140.00 cr
27 May 2016
Incorporated
Registered with Roc Mumbai
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Jatas Herbals Limited U24230AP2022PLC122248 Kakinada, Andhra Pradesh, India
Canaan Lifescience Pharmaceuticals Limited U74999DL2017PLC325227 New Delhi, Delhi, India
Bisleri U24110MH1936PTC002484 Mumbai, Maharashtra, India
Avon Lifesciences L24110TG1993PLC016112 Hyderabad, Telangana, India
Sangharsh Life Sciences Private Limited U24230GJ2021PTC120188 Ahmedabad, Gujarat, India
Varenyam Biolifesciences Private Limited U24290GJ2022PTC133332 Vadodara, Gujarat, India
Medisum Biotech Private Limited U24297DL2022PTC398224 Delhi, Delhi, India
Scg Healthcare Private Limited U24290HR2021PTC099312 Gurgaon, Haryana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Mape Pharmascience Llp before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Mape Pharmascience Llp: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 50/100, margin trends, ownership structure and peer set for Mape Pharmascience Llp - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 87/100, distress signals and MSME payment-delay disclosures - know whether Mape Pharmascience Llp pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Mape Pharmascience Llp - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Mape Pharmascience Llp an active company?

Mape Pharmascience Llp has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Mape Pharmascience Llp financially healthy?

Mape Pharmascience Llp has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Mape Pharmascience Llp?

Its overall Trust Score is 87/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Mape Pharmascience Llp?

See the directors and ownership sections above for board and shareholding detail. 2 active director(s) are on record.

Does Mape Pharmascience Llp have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.

Is Mape Pharmascience Llp up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Mape Pharmascience Llp?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.